Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treating tinea capitis: should ketoconazole replace griseofulvin?

R R Tanz1, A A Hebert, N B Esterly

  • 1Division of General and Emergency Pediatrics, Northwestern University Medical School, Chicago, IL.

The Journal of Pediatrics
|June 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Managing pediatric psoriasis: update on treatments and challenges-a review.

The Journal of dermatological treatment·2022
Same author

Development and validation of the Axillary Sweating Daily Diary: a patient-reported outcome measure to assess axillary sweating severity.

Journal of patient-reported outcomes·2019
Same author

Use of an alternative method to evaluate erythema severity in a clinical trial: difference in vehicle response with evaluation of baseline and postdose photographs for effect of oxymetazoline cream 1·0% for persistent erythema of rosacea in a phase IV study.

The British journal of dermatology·2018
Same author

Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME).

The British journal of dermatology·2014
Same author

Addition of topical pimecrolimus to once-daily mid-potent steroid confers no short-term therapeutic benefit in the treatment of severe atopic dermatitis; a randomized controlled trial.

The British journal of dermatology·2007
Same author

Congenital Volkmann ischaemic contracture: a case report and review.

The British journal of dermatology·2004
Same journal

Blood-Based Biomarkers Predict Cerebral Palsy and Cognitive Delay in Hypoxic-Ischemic Encephalopathy: A Secondary Analysis of the HEAL Randomized Controlled Trial.

The Journal of pediatrics·2026
Same journal

Does Mild Head Injury in Childhood Affect Later School Performance? A Sibling Comparison Cohort Study.

The Journal of pediatrics·2026
Same journal

Risk Factors for Mortality and Age at Discharge in Preterm Infants with Congenital Heart Disease.

The Journal of pediatrics·2026
Same journal

To Cool or Not to Cool in Low- and Middle-Income Countries:? A Call for Resources, Training and Shared Knowledge.

The Journal of pediatrics·2026
Same journal

Responsible Research Practices in Pediatrics: How Reporting Guidelines Can Be Used to Improve Trial Design and Conduct.

The Journal of pediatrics·2026
Same journal

Safety of 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Children in the Vaccine Adverse Event Reporting System.

The Journal of pediatrics·2026
See all related articles

Griseofulvin demonstrated superior efficacy over ketoconazole in treating tinea capitis, with 96% of patients responding well. This randomized trial suggests griseofulvin remains the preferred treatment for this fungal infection.

Area of Science:

  • Dermatology
  • Mycology
  • Infectious Diseases

Background:

  • Tinea capitis is a common superficial fungal infection affecting the scalp.
  • Effective treatment options are crucial to prevent transmission and complications.
  • Griseofulvin and ketoconazole are established antifungal agents.

Purpose of the Study:

  • To compare the efficacy and safety of griseofulvin versus ketoconazole for treating tinea capitis.
  • To evaluate treatment outcomes based on fungal culture and clinical assessment.
  • To determine the optimal antifungal drug for tinea capitis.

Main Methods:

  • A randomized, double-blind comparison of griseofulvin and ketoconazole.
  • Seventy-nine patients with tinea capitis were enrolled.

Related Experiment Videos

  • Outcomes assessed via fungal cultures and clinical severity scores over 12 weeks.

    • Main Results:

    • Griseofulvin achieved a 96% success rate, compared to 73% for ketoconazole.
    • Trichophyton tonsurans was the predominant pathogen identified.
    • Potassium hydroxide (KOH) preparation showed poor correlation with fungal culture results.

    Conclusions:

    • Griseofulvin is more effective than ketoconazole for tinea capitis treatment.
    • Griseofulvin should remain the first-line drug of choice.
    • No significant adverse reactions were noted for either medication.